Chugai (Formerly Chugai Pharmaceutical Co. Ltd.)
1-9, Kyobashi 2-chome, Chuo-ku
8 articles with Chugai (Formerly Chugai Pharmaceutical Co. Ltd.)
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that Chugai Pharmaceutical Co., Ltd. has in-licensed the rights for AT-527 for the treatment of COVID-19 in Japan from Roche.
New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A
Chugai Pharmaceutical Co., Ltd. announced that the second interim analysis results from the phase IIIb STASEY study reinforce the safety profile of Hemlibra® characterized in the phase III HAVEN studies
Agreement aims to expedite local biomarker testing of NSCLC patients eligible for entrectinib in Japan
Genedata Profiler used for biomarker discovery and validation projects in support of Chugai’s early proof of concept research initiatives
Foundation Medicine and Chugai Announce Partnership with National Cancer Center for the Use of FoundationOne®Liquid in the Third Stage of SCRUM-Japan
SCRUM-Japan aims to apply blood-based genomic insights to inform and accelerate the development of precision medicine approaches for patients with advanced cancers
Results from Phase III SAkuraSky Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in The New England Journal of Medicine Online
Satralizumab added to baseline immunosuppressant therapy significantly reduced risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).
ugai Pharmaceutical Co., Ltd., a member of the Roche Group, will extend the company's licensed access to the Immunogenicity Screening and Protein Reengineering Interface toolkit developed by EpiVax, Inc.